---
title: "Doxorubicin plus Paclitaxel: Repurposed combination with potential activity in diffuse large B‑cel"
id: "pubmed-42235267"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-42235267"
content_type: "clinical_feed_article"
specialty: "Pharmacology"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/42235267/"
doi: "10.1016/j.compbiomed.2026.111781"
published_at: "2026-08-15T00:00:00.000Z"
evidence_level: "Journal Article"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Doxorubicin plus Paclitaxel: Repurposed combination with potential activity in diffuse large B‑cel
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-42235267
- **Specialty:** [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/42235267/)
- **DOI:** [10.1016/j.compbiomed.2026.111781](https://doi.org/10.1016%2Fj.compbiomed.2026.111781)
- **Published At:** 2026-08-15T00:00:00.000Z
- **Evidence Rating:** Journal Article
## Executive GIST (TL;DR)
- The study applied an integrative **drug repurposing** workflow combining in silico network pharmacology, molecular docking, and in vitro validation to identify candidate therapies for **Diffuse Large B‑Cell Lymphoma (DLBCL)**. - Researchers compiled DLBCL‑associated genes from DisGeNET and GeneCards and identified 144 overlapping genes (OGs) for downstream analysis. - Functional enrichment of OGs implicated pathways including **PI3K‑Akt signalling**, apoptosis, and cell cycle regulation as relevant to DLBCL pathobiology. - Protein-protein interaction (PPI) network analysis in STRING and Cytoscape identified seven hub genes; **AKT1, TP53, MYC, and STAT3** were highlighted as key regulatory targets and were validated for expression using GEPIA2. - Candidate drugs were screened from DSigDB and DrugMAP; molecular docking with AutoDock Vina identified compounds with high binding affinities (≤ −8.0 kcal/mol), notably **Doxorubicin**, **Paclitaxel**, Sorafenib, Masoprocol, and Bortezomib against hub proteins. - In vitro experiments using 2PK‑3 DLBCL cells evaluated cytotoxicity, morphology changes, and reactive oxygen species (ROS) after treatment with Doxorubicin, Paclitaxel, and their combination. - Combined treatment with Doxorubicin and Paclitaxel produced greater cytotoxicity, increased morphological disruption, and higher ROS generation than single‑agent treatments in the cell model. - The authors conclude that the **Doxorubicin–Paclitaxel** combination shows therapeutic potential in DLBCL and that repurposing approved antitumor agents via integrative computational and experimental approaches may expedite combinatorial therapy development. - Conflict of interest: authors declared no competing financial interests or personal relationships. - Details such as specific docking scores per target, exact concentrations and exposure times used in in vitro assays, and statistical parameters were not reported in the abstract and require consulting the full text for complete methodological and quantitative information.
## Clinical Analysis & Structured Key Points
Clipboard, Search History, and several other advanced features are temporarily unavailable. [ Skip to main page content ](https://pubmed.ncbi.nlm.nih.gov/42235267/#article-details) ![U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png) An official website of the United States government Here's how you know ![Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. ![Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg) ](https://www.ncbi.nlm.nih.gov/) [Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42235267%2F) Show account info Close #### Account Logged in as: **username** * [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/) * [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/) * [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/) * [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/42235267/) [Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/42235267/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/42235267/) [ ![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/af7de7da-df5d-41c6-8de4-8c266af8ccfb/core/images/pubmed-logo-blue.svg) ](https://pubmed.ncbi.nlm.nih.gov/) [ ](https://pubmed.ncbi.nlm.nih.gov/42235267/ "Show search bar") Search: [](https://pubmed.ncbi.nlm.nih.gov/42235267/ "Clear search input")Search [Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/clipboard/) [ User Guide ](https://pubmed.ncbi.nlm.nih.gov/help/) Save Email Send to * [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/42235267/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42235267%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42235267%2F%23open-collections-panel) * [Citation manager](https://pubmed.ncbi.nlm.nih.gov/42235267/) Display options Display options Format Abstract PubMed PMID ## Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel ## Email citation Email address has not been verified. Go to [ My NCBI account settings ](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel ### Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42235267/) Add Cancel ### Add to My Bibliography * My Bibliography Unable to load your delegates due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42235267/) Add Cancel ## Your saved search Name of saved search: Search terms: [Test search terms](https://pubmed.ncbi.nlm.nih.gov/42235267/) Would you like email updates of new search results? Saved Search Alert Radio Buttons * Yes * No Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/)) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel ## Create a file for external citation management software Create file Cancel ## Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy ### Full text links [![Elsevier Science full text link](https://cdn.ncbi.nlm.nih.gov/corehtml/query/egifs/https:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif) Elsevier Science ](https://linkinghub.elsevier.com/retrieve/pii/S0010-4825\(26\)00345-8 "See full text options at Elsevier Science") [ Full text links ](https://pubmed.ncbi.nlm.nih.gov/42235267/) ### Actions Cite Collections Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42235267/) Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID ### Page navigation * [ Title & authors ](https://pubmed.ncbi.nlm.nih.gov/42235267/#heading) * [ Abstract ](https://pubmed.ncbi.nlm.nih.gov/42235267/#abstract) * [ Conflict of interest statement ](https://pubmed.ncbi.nlm.nih.gov/42235267/#conflict-of-interest) * [Similar articles](https://pubmed.ncbi.nlm.nih.gov/42235267/#similar) * [ MeSH terms ](https://pubmed.ncbi.nlm.nih.gov/42235267/#mesh-terms) * [ Substances ](https://pubmed.ncbi.nlm.nih.gov/42235267/#substances) * [Related information](https://pubmed.ncbi.nlm.nih.gov/42235267/#related-links) * [ LinkOut - more resources ](https://pubmed.ncbi.nlm.nih.gov/42235267/#linkout) Title & authors Abstract Conflict of interest statement Similar articles MeSH terms Substances Related information LinkOut - more resources Comput Biol Med Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Comput+Biol+Med%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Comput+Biol+Med%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42235267/) . 2026 Aug 15:213:111781. doi: 10.1016/j.compbiomed.2026.111781. Epub 2026 Jun 3. # Synergistic drug repurposing strategy identifies doxorubicin and paclitaxel as potential combination therapy for diffuse large B-cell lymphoma [Prankur Awasthi](https://pubmed.ncbi.nlm.nih.gov/?term=Awasthi+P&cauthor_id=42235267)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42235267/#full-view-affiliation-1 "Amity Institute of Biotechnology, Amity University Uttar Pradesh, Lucknow, 226028, India."), [Anees Ahmad](https://pubmed.ncbi.nlm.nih.gov/?term=Ahmad+A&cauthor_id=42235267)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42235267/#full-view-affiliation-2 "Natural Products Laboratory, Department of Bioengineering, Integral University, Lucknow, Uttar Pradesh, India."), [Nishant Kumar Singh](https://pubmed.ncbi.nlm.nih.gov/?term=Singh+NK&cauthor_id=42235267)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42235267/#full-view-affiliation-1 "Amity Institute of Biotechnology, Amity University Uttar Pradesh, Lucknow, 226028, India."), [Iffat Zareen Ahmad](https://pubmed.ncbi.nlm.nih.gov/?term=Ahmad+IZ&cauthor_id=42235267)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42235267/#full-view-affiliation-2 "Natural Products Laboratory, Department of Bioengineering, Integral University, Lucknow, Uttar Pradesh, India."), [Saba Hasan](https://pubmed.ncbi.nlm.nih.gov/?term=Hasan+S&cauthor_id=42235267)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42235267/#full-view-affiliation-3 "Amity Institute of Biotechnology, Amity University Uttar Pradesh, Lucknow, 226028, India. Electronic address: shasan@lko.amity.edu.") Affiliations Expand ### Affiliations * 1 Amity Institute of Biotechnology, Amity University Uttar Pradesh, Lucknow, 226028, India. * 2 Natural Products Laboratory, Department of Bioengineering, Integral University, Lucknow, Uttar Pradesh, India. * 3 Amity Institute of Biotechnology, Amity University Uttar Pradesh, Lucknow, 226028, India. Electronic address: shasan@lko.amity.edu. * PMID: **42235267** * DOI: [ 10.1016/j.compbiomed.2026.111781 ](https://doi.org/10.1016/j.compbiomed.2026.111781) Item in Clipboard # Synergistic drug repurposing strategy identifies doxorubicin and paclitaxel as potential combination therapy for diffuse large B-cell lymphoma Prankur Awasthi et al. Comput Biol Med. 2026. Show details Display options Display options Format Abstract PubMed PMID Comput Biol Med Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Comput+Biol+Med%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Comput+Biol+Med%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42235267/) . 2026 Aug 15:213:111781. doi: 10.1016/j.compbiomed.2026.111781. Epub 2026 Jun 3. ### Authors [Prankur Awasthi](https://pubmed.ncbi.nlm.nih.gov/?term=Awasthi+P&cauthor_id=42235267)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42235267/#short-view-affiliation-1 "Amity Institute of Biotechnology, Amity University Uttar Pradesh, Lucknow, 226028, India."), [Anees Ahmad](https://pubmed.ncbi.nlm.nih.gov/?term=Ahmad+A&cauthor_id=42235267)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42235267/#short-view-affiliation-2 "Natural Products Laboratory, Department of Bioengineering, Integral University, Lucknow, Uttar Pradesh, India."), [Nishant Kumar Singh](https://pubmed.ncbi.nlm.nih.gov/?term=Singh+NK&cauthor_id=42235267)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42235267/#short-view-affiliation-1 "Amity Institute of Biotechnology, Amity University Uttar Pradesh, Lucknow, 226028, India."), [Iffat Zareen Ahmad](https://pubmed.ncbi.nlm.nih.gov/?term=Ahmad+IZ&cauthor_id=42235267)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42235267/#short-view-affiliation-2 "Natural Products Laboratory, Department of Bioengineering, Integral University, Lucknow, Uttar Pradesh, India."), [Saba Hasan](https://pubmed.ncbi.nlm.nih.gov/?term=Hasan+S&cauthor_id=42235267)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42235267/#short-view-affiliation-3 "Amity Institute of Biotechnology, Amity University Uttar Pradesh, Lucknow, 226028, India. Electronic address: shasan@lko.amity.edu.") ### Affiliations * 1 Amity Institute of Biotechnology, Amity University Uttar Pradesh, Lucknow, 226028, India. * 2 Natural Products Laboratory, Department of Bioengineering, Integral University, Lucknow, Uttar Pradesh, India. * 3 Amity Institute of Biotechnology, Amity University Uttar Pradesh, Lucknow, 226028, India. Electronic address: shasan@lko.amity.edu. * PMID: **42235267** * DOI: [ 10.1016/j.compbiomed.2026.111781 ](https://doi.org/10.1016/j.compbiomed.2026.111781) Item in Clipboard Full text links Cite Display options Display options Format Abstract PubMed PMID ## Abstract **Purpose:** Diffuse Large B-Cell Lymphoma (DLBCL) is the most common and aggressive subtype of non-Hodgkin lymphoma, characterized by clinical heterogeneity and chemoresistance. About 30% of patients relapse or develop refractory disease despite therapy. This study aimed to identify repurposed antitumor agents with potentially synergistic efficacy against DLBCL through an integrative in silico and in vitro approach. **Methods:** DLBCL-associated genes were obtained from DisGeNET and GeneCards, and overlapping genes (OGs) were identified via Venny v2.1.0. Functional enrichment analysis of OGs was performed using ShinyGO v0.77, while protein-protein interaction (PPI) networks were generated with STRING v11.5 and visualized in Cytoscape v3.10 to identify hub genes. Expression validation was conducted using GEPIA2. Potential drugs were screened from DSigDB and DrugMAP, and molecular docking using AutoDock Vina v1.2.0 assessed binding affinities of candidate compounds with hub gene proteins. In vitro assays employing 2PK-3 DLBCL cells evaluated cytotoxicity and oxidative stress induced by Doxorubicin and Paclitaxel, both alone and combined, through morphological analysis, MTT viability, and ROS assays. **Results:** A total of 144 OGs were identified, with enrichment analysis highlighted PI3K-Akt signalling, apoptosis, and cell cycle regulation. Seven hub genes were identified, among which AKT1, TP53, MYC, and STAT3 emerged as key regulatory targets. Docking demonstrated high binding affinities (≤-8.0 kcal/mol) for Doxorubicin, Paclitaxel, Sorafenib, Masoprocol, and Bortezomib. Combined Doxorubicin and Paclitaxel treatment exhibited enhanced cytotoxicity, morphological disruption, and elevated ROS generation compared to single-drug treatments. **Conclusion:** This integrative study highlights the therapeutic potential of Doxorubicin and Paclitaxel against DLBCL, supporting drug repurposing as a promising strategy for developing effective combinatorial therapies. **Keywords:** Combination therapy; Diffuse large B-Cell lymphoma; Doxorubicin; Drug repurposing; Molecular docking; Network pharmacology; PI3K–Akt signalling; Paclitaxel; TP53. Copyright © 2026. Published by Elsevier Ltd. [PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) ## Conflict of interest statement Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. ## Similar articles * [ Multi-omics and experimental validation reveal mechanism of compound mylabris capsules in treating diffuse large B-cell lymphoma. ](https://pubmed.ncbi.nlm.nih.gov/40615583/) Wang C, Wang J, Yu J, Feng N, Zhang R, Ma J, Gao H, Zhou G, Li X.Wang C, et al.Sci Rep. 2025 Jul 4;15(1):23856. doi: 10.1038/s41598-025-09767-5.Sci Rep. 2025.PMID: 40615583Free PMC article. * [ Uncovering the antiproliferative effects of magnolol in liver cancer: a multi-omics study integrating computational chemistry, network pharmacology, bioinformatics and in vitro experimental validations. ](https://pubmed.ncbi.nlm.nih.gov/41483318/) Cai Y, Liu Y, Tian C, Liu F, Wang X.Cai Y, et al.Mol Divers. 2026 Aug;30(4):5449-5471. doi: 10.1007/s11030-025-11443-9. Epub 2026 Jan 3.Mol Divers. 2026.PMID: 41483318 * [ Targeting EP300 in diffuse large b-cell lymphoma: efficacy of A485 and synergistic effects with XPO1 inhibition. ](https://pubmed.ncbi.nlm.nih.gov/40437414/) Jiang Y, Xing D, He X, Wu W, Xu H, Sun H, Zhai Y, Luo K, Zhao Z.Jiang Y, et al.BMC Cancer. 2025 May 28;25(1):955. doi: 10.1186/s12885-025-14257-y.BMC Cancer. 2025.PMID: 40437414Free PMC article. * [ Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. ](https://pubmed.ncbi.nlm.nih.gov/12662126/) Plosker GL, Figgitt DP.Plosker GL, et al.Drugs. 2003;63(8):803-43. doi: 10.2165/00003495-200363080-00005.Drugs. 2003.PMID: 12662126Review. * [ Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review. ](https://pubmed.ncbi.nlm.nih.gov/26654227/) Camicia R, Winkler HC, Hassa PO.Camicia R, et al.Mol Cancer. 2015 Dec 11;14:207. doi: 10.1186/s12943-015-0474-2.Mol Cancer. 2015.PMID: 26654227Free PMC article.Review. [ See all similar articles ](https://pubmed.ncbi.nlm.nih.gov/?linkname=pubmed_pubmed&from_uid=42235267) ## MeSH terms * Antineoplastic Combined Chemotherapy Protocols* / pharmacology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Antineoplastic+Combined+Chemotherapy+Protocols%2Fpharmacology%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Antineoplastic+Combined+Chemotherapy+Protocols) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42235267/) * Apoptosis / drug effects Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Apoptosis%2Fdrug+effects%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Apoptosis) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42235267/) * Cell Line, Tumor Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Cell+Line%2C+Tumor%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Cell+Line%2C+Tumor) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42235267/) * Doxorubicin* / chemistry Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Doxorubicin%2Fchemistry%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Doxorubicin) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42235267/) * Doxorubicin* / pharmacology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Doxorubicin%2Fpharmacology%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Doxorubicin) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42235267/) * Drug Repositioning* Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Drug+Repositioning%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Drug+Repositioning) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42235267/) * Drug Synergism Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Drug+Synergism%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Drug+Synergism) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42235267/) * Gene Expression Regulation, Neoplastic / drug effects Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Gene+Expression+Regulation%2C+Neoplastic%2Fdrug+effects%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Gene+Expression+Regulation%2C+Neoplastic) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42235267/) * Humans Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Humans%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Humans) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42235267/) * Lymphoma, Large B-Cell, Diffuse* / drug therapy Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Lymphoma%2C+Large+B-Cell%2C+Diffuse%2Fdrug+therapy%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Lymphoma%2C+Large+B-Cell%2C+Diffuse) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42235267/) * Lymphoma, Large B-Cell, Diffuse* / genetics Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Lymphoma%2C+Large+B-Cell%2C+Diffuse%2Fgenetics%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Lymphoma%2C+Large+B-Cell%2C+Diffuse) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42235267/) * Lymphoma, Large B-Cell, Diffuse* / metabolism Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Lymphoma%2C+Large+B-Cell%2C+Diffuse%2Fmetabolism%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Lymphoma%2C+Large+B-Cell%2C+Diffuse) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42235267/) * Lymphoma, Large B-Cell, Diffuse* / pathology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Lymphoma%2C+Larg
## Related Clinical Research

- [Low-dose vemurafenib plus rituximab (Scripps regimen) for frontline and relapsed hairy cell leukem](https://medichelpline.com/clinical-feed/pubmed-42308249.md) (DOI: 10.1182/bloodadvances.2025019243)
- [GAA as a Prognostic Biomarker and Therapeutic Target in Angioimmunoblastic T‑cell Lymphoma — Full](https://medichelpline.com/clinical-feed/frontiers-in-immunology-16-multi-omics-analysis-identifies-gaa-as-an-independent-poor-prognostic-biomarker.md)
- [Anaphylactic reaction to dacarbazine on second infusion in Hodgkin lymphoma patient](https://medichelpline.com/clinical-feed/pubmed-42578872.md) (DOI: 10.1177/10781552261477104)
- [HCT–ASCT validated as superior consolidation versus non‑myeloablative chemoimmunotherapy for PCNSL](https://medichelpline.com/clinical-feed/nature-reviews-clinical-oncology-0-hct-asct-confirmed-as-standard-of-care-consolidation-therapy-for-pcnsl.md)
- [Probable CLIPPERS in a Patient with Cutaneous T‑Cell Lymphoma Remission: 5‑Year Follow‑Up (Report](https://medichelpline.com/clinical-feed/frontiers-in-immunology-11-case-report-probable-clippers-in-a-patient-with-cutaneous-t-cell-lymphoma-in.md)

## Navigation
- [← Back to Pharmacology Feed](https://medichelpline.com/clinical-feed/pharmacology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.